- Home
- MLKN vs SYRE Comparison
MLKN vs SYRE Comparison
Compare MLKN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLKN
- SYRE
- Stock Information
- Founded
- MLKN 1905
- SYRE 2013
- Country
- MLKN United States
- SYRE United States
- Employees
- MLKN N/A
- SYRE N/A
- Industry
- MLKN Office Equipment/Supplies/Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- MLKN Consumer Discretionary
- SYRE Health Care
- Exchange
- MLKN Nasdaq
- SYRE Nasdaq
- Market Cap
- MLKN 1.2B
- SYRE 1.1B
- IPO Year
- MLKN N/A
- SYRE 2016
- Fundamental
- Price
- MLKN $15.98
- SYRE $28.97
- Analyst Decision
- MLKN
- SYRE Strong Buy
- Analyst Count
- MLKN 0
- SYRE 4
- Target Price
- MLKN N/A
- SYRE $52.67
- AVG Volume (30 Days)
- MLKN 1.2M
- SYRE 656.3K
- Earning Date
- MLKN 12-17-2025
- SYRE 11-04-2025
- Dividend Yield
- MLKN 4.71%
- SYRE N/A
- EPS Growth
- MLKN N/A
- SYRE N/A
- EPS
- MLKN N/A
- SYRE N/A
- Revenue
- MLKN $3,764,100,000.00
- SYRE N/A
- Revenue This Year
- MLKN $5.40
- SYRE N/A
- Revenue Next Year
- MLKN $3.96
- SYRE N/A
- P/E Ratio
- MLKN N/A
- SYRE N/A
- Revenue Growth
- MLKN 5.37
- SYRE N/A
- 52 Week Low
- MLKN $13.77
- SYRE $10.91
- 52 Week High
- MLKN $25.96
- SYRE $29.29
- Technical
- Relative Strength Index (RSI)
- MLKN 55.72
- SYRE 76.07
- Support Level
- MLKN $13.77
- SYRE $23.01
- Resistance Level
- MLKN $15.53
- SYRE $25.42
- Average True Range (ATR)
- MLKN 0.61
- SYRE 1.74
- MACD
- MLKN 0.24
- SYRE 0.33
- Stochastic Oscillator
- MLKN 96.41
- SYRE 97.66
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.